• Round co-led by EQT Life Sciences and Forbion
• Series A financing will support clinical development of the lead program in amyotrophic lateral sclerosis (ALS) and preclinical development of pipeline programs based on VectorY’s broad technology platform

Copenhagen, Denmark, November 7th 2023 — Sunstone Life Science Ventures (Sunstone), a leading
Nordic venture capital firm, is excited to announce its participation in a EUR 57 million Series A
funding round for Kynexis B.V., a pioneering biotech company dedicated to advancing treatments for
cognitive impairment associated with schizophrenia. Jacob Lange Moresco, Investment Director with
Sunstone, will be joining Kynexis’ board of directors as part of this investment.

This significant funding round was led by European investor Forbion alongside Ysios Capital and
Sunstone. The financing will support Kynexis’ innovative approach, which combines cutting-edge
patient selection methods with a deep understanding of the genetic links underlying their lead
molecule’s mechanism of action. The unique combination of strategies holds the promise of not only
improving the effectiveness of treatment but also personalizing it to individual patients, a crucial
advancement in the field of mental health therapeutics.

The lead program, KYN-5356, is designed to regulate kynurenic acid levels in the brain and in turn
address the cognitive impairment often associated with schizophrenia, a debilitating condition that
affects millions of individuals worldwide. Cognitive impairment can significantly hinder the quality of
life for those living with schizophrenia, making this research a critical area of focus for the medical
community.

Kynexis’ leadership team holds extensive experience in psychiatry, neurology and drug discovery and
includes CEO Kees Been, CMO Jens Wendland as well as Executive Chair Peter Høngaard Andersen.
Jacob Lange Moresco expressed his enthusiasm about this investment and his role on Kynexis’
board, stating, “We believe that Kynexis’ approach to addressing cognitive impairment associated
with schizophrenia has the potential to transform the lives of countless individuals and their families.
We are thrilled to support this world-class team and their important work towards better
therapeutic options for individuals living with mental illness.”

About Kynexis
Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach
to advance a potential first-in-class treatment for cognitive impairment associated with
schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the
underlying causal human biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the
kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that
is potent and highly selective for KAT-II. The Company also has a subsidiary in the United States and
a Massachusetts office in Cambridge. (Kynexis Therapeutics Inc.).

About Sunstone Life Science Ventures
Sunstone Life Science Ventures is an independent European venture capital investment firm
founded in 2007 by an international team of industry experts with combined entrepreneurial,
operational and financial experience. Managing total funds of €500 million, Sunstone focuses on
developing and expanding early-stage Life Science companies with strong potential to achieve global
success in their markets. Since inception, Sunstone has invested in more than 60 companies, and has
completed more than 25 successful IPOs and large M&A transactions.
For more information about Kynexis, please visit kynexistx.com
For more information about Sunstone, please visit sunstone.eu

Copenhagen, Denmark and Marseille, France, Oct 31, 2023 – Sunstone Life Science Ventures
(Sunstone), a leading European venture capital firm focused on life science therapeutics, today
announced that Sunstone’s Fund IV has invested in the Series A financing round of DiogenX now
increased to €33.5 million ($33.8M). In May, DiogenX, a biotech company focused on regenerating
insulin-producing beta cells for the treatment of diabetes, had announced its initial Series A financing
round.

DiogenX was founded in 2020 based on the groundbreaking research of Professor Patrick
Collombat, a world-renowned expert in pancreatic beta cell regeneration. The Company’s lead
program is a first-in-class recombinant protein that aims at replicating insulin-producing beta
cells in the pancreas. This novel approach has the potential to offer a disease-modifying therapy
for type 1 diabetes, a chronic and life-threatening condition that affects millions of people
worldwide.

In this Series A round, Sunstone LSV Fund IV joins lead investors Roche Venture Fund and
Boehringer Ingelheim Venture Fund (BIVF), alongside new investors Eli Lilly and Company and
Omnes and existing investors JDRF T1D Fund and AdBio partners. The funding will enable
DiogenX to advance its lead candidate towards clinical development.
“We are very impressed by the scientific achievements and the vision of DiogenX’s team. We
believe that their approach to regenerate beta cells has the potential to transform the treatment
landscape for type 1 diabetes and to improve the lives of millions of patients” said Claus
Andersson, General Partner at Sunstone and board member of DiogenX. “We are delighted to join
this strong syndicate of specialized investors and to support DiogenX in its next phase of growth.”
“Sunstone is a highly respected and experienced investor in the European biotech ecosystem.
We are thrilled to have them on board as we work towards the clinic with our lead program,” said
Benjamin Charles, co-founder and CEO of DiogenX. “We are grateful for the continued support
of our existing investors and the trust of our new investors. Together, we share a common vision
to bring innovative solutions for patients with type 1 diabetes.”

About Sunstone
Sunstone is an independent European venture capital investment firm founded in 2007.
Sunstone focuses on scientifically advanced assets, and invests to develop and expand preclinical stage life science companies with strong potential to achieve global success within their
therapeutic fields. Sunstone has invested in more than 50 companies and has completed more
than 23 successful exits and IPOs. Sunstone ranks among the most active European investors in
life science therapeutics. For more information, please visit sunstone.eu.

About DiogenX
DiogenX is a biotech company focused on regenerating insulin-producing beta cells for the
treatment of diabetes.
Founded in 2020 based on the research of leading type 1 (T1D) diabetes scientist Patrick
Collombat on pancreatic beta-cell regeneration, DiogenX is developing first-in-class
recombinant proteins designed for the treatment of T1D.
DiogenX’s lead program is focused on modulating the Wnt/β-catenin signalling pathway to
regenerate pancreatic insulin-producing beta cells to offer a disease-modifying therapy for type
1 diabetes. It is currently in preclinical development.
DiogenX is supported by a network of world-leading experts in diabetes and a consortium of
investors including diabetes and biopharma leaders Boehringer Ingelheim Venture Fund, Roche
Venture Fund, Eli Lilly and Company, Omnes, JDRF T1D Fund, Sunstone and AdBio partners. The
company founded by Patrick Collombat, Jean-Pascal Tranié and Benjamin Charles, is based in
Marseille, France, with research labs in Nice, France.
www.diogenx.com

Contact
Sunstone: Claus Andersson, PhD, General Partner, andersson@sunstone.eu, +45 22 70 50 65
DiogenX: Andrew Lloyd & Associates / SaƯiyah Khalique – Celine Gonzalez
saƯiyah@ala.associates / celine@ala.associates, UK: +44 1273 952 481, US: +1 203 724 595.
@ALA_Group

In partnership with property owner Amvest, Het Gastenhuis is realizing sustainable guest houses. Most of these houses are fully independent from natural gas and are equipped with solar panels and heat pumps. Only a few locations still remain connected to the gas network solely as a backup for the heat pumps. A few older buildings that have been converted to Gastenhuizen are currently also in the process of becoming more sustainable. Low energy consumption (low CO2 emissions) and a comfortable indoor climate are key aspects that are taking into account.

Furthermore, the Amvest Living & Care Fund, the developer and owner of het Gastenhuis, has been named the most sustainable healthcare real estate fund in Western Europe for the fourth time. The Global Real Estate Sustainability Benchmark (GRESB), the global standard for sustainability in real estate, announced this in October 2023.

With this Het Gastenhuis is working with Amvest to continue to build a more sustainable future.”

LONDON–(BUSINESS WIRE)– Clinisupplies Limited (“Clinisupplies”), a leading manufacturer and supplier of continence care consumables, today announced the acquisition of the Aquaflush transanal irrigation (“TAI”) business from Renew Medical Inc. and Renew Medical UK Limited, a US and UK manufacturer of continence products (together “Renew”).

The acquisition of the Aquaflush TAI range will enable Clinisupplies to expand its offering to include bowel management products, while also supporting patients living with chronic bowel issues through its nursing services.

Clinisupplies continues to integrate fast growing businesses, strengthening its position as a leading UK based direct-to-consumer chronic care company, providing continence care products and nursing services that helps support the NHS. Earlier this year, following an investment by funds managed by KKR, Clinisupplies announced the acquisition of Great Bear Healthcare, a UK-based manufacturer and supplier of urinary continence care products for managing acute and chronic conditions in the community.

Paul Cook, CEO at Clinisupplies, commented: “The Aquaflush business is a perfect fit with Clinisupplies’ purpose of helping people with continence issues to live more freely through the products and services we provide. It is our ambition to continue broadening this range of products and services in order to reach more consumers and healthcare professionals and to better support their needs. We are excited to add the Aquaflush range to our portfolio and to continue building on our growing position in the UK and around the world.”

Jason Tate, CEO at Renew, commented: “We have been delighted with the success Renew has enjoyed in recent years, and for the growing number of people who rely on the innovative range of Aquaflush TAI products. We are excited to see the next phase of development for the range and the growing support for Aquaflush users under the team at Clinisupplies.”

KKR invested in Clinisupplies through KKR Health Care Strategic Growth Fund II, a $4.0 billion fund focused on investing in high-growth health care companies. KKR has a long track record of supporting health care companies globally, having invested approximately $19 billion in the sector since 2004.

About Clinisupplies

Clinisupplies is a manufacturer and supplier of medical appliances specialising in continence products for managing acute and chronic conditions. Employing over 500 people in the UK, China and India, Clinisupplies provides its products to the NHS and delivers direct to patients’ homes through Clinidirect, its dispensing appliance contractor.

Clinisupplies is focused on developing products which are simple and discreet to use. Its product development team works with clinicians and patients to develop a strong product pipeline to be manufactured at its CE, ISO, US FDA approved facilities.

Please visit www.clinisupplies.co.uk for further information.

About KKR

KKR is a leading global investment firm that offers alternative asset management as well as capital markets and insurance solutions. KKR aims to generate attractive investment returns by following a patient and disciplined investment approach, employing world-class people, and supporting growth in its portfolio companies and communities. KKR sponsors investment funds that invest in private equity, credit and real assets and has strategic partners that manage hedge funds. KKR’s insurance subsidiaries offer retirement, life and reinsurance products under the management of Global Atlantic Financial Group. References to KKR’s investments may include the activities of its sponsored funds and insurance subsidiaries. For additional information about KKR & Co. Inc. (NYSE: KKR), please visit KKR’s website at www.kkr.com. For additional information about Global Atlantic Financial Group, please visit Global Atlantic Financial Group’s website at www.globalatlantic.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231026271179/en/

FGS Global
Alastair Elwen / Sophia Johnston
Telephone: +44 20 7251 3801
Email: KKR-Lon@FGSGlobal.com

Source: KKR

Sunrise Medical, a world leader in advanced assistive mobility solutions, is pleased to announce its strategic acquisition of Ride Designs, a renowned industry leader in premium custom seating systems for wheelchair riders. This acquisition marks a significant expansion of Sunrise Medical’s custom seating offerings, clinical expertise, and service capabilities, perfectly complementing the extensive range of manual and powered mobility products Sunrise Medical already offers.

Founded in 1998 and headquartered in Denver, USA, Ride Designs has built its reputation as an industry leader in designing and delivering highly specialised seating systems for wheelchair riders.

In recent years, Ride Designs has also been successfully developing, implementing, and optimizing the advanced 3D printing technologies for mass production of such highly customised products.

The company has thrived by adhering to a set of core principles backed by the in-depth expertise of its founders Tom Hetzel and Joe Bieganek, and the heritage from the prosthetics and orthotics industry, which include direct rider engagement through the Aspen Seating Clinic. In addition, the portfolio of Ride Designs benefits from evidence-based product and technology development supported by broad collaborations and research with reputable institutions and universities. This ensures that the company’s leading-edge innovations are always well integrated with user centric approach and science backed data.

The unique market reach of Ride Designs, through extensive clinical education and certification of skilled complex rehabilitation technology clinicians and providers, also demonstrates a steadfast commitment to clinically differentiated solutions that are optimized to personalized customer care.

Thomas Babacan, President and CEO of Sunrise Medical, said: “We’re very excited to welcome Ride Designs into the Sunrise Medical family. We firmly believe that this acquisition has high strategic importance and offers mutual benefits for both parties. By joining forces with Ride Designs, Sunrise adds a high-end custom seating offering to our Seating and Positioning product portfolio, similar to RGK for the manual wheelchairs range and Magic for the power wheelchairs range.”

“The acquisition not only addresses and significantly expands the broad spectrum of seating and positioning requirements for wheelchair riders worldwide, but also brings valuable clinical expertise and advanced 3D printing technologies and competences into the Group. Together with Ride’s seasoned management team and highly skilled workforce, Sunrise Medical now has an even stronger product range, clinical expertise, and operational competences to offer the best suited seating solutions to all wheelchair riders. This optimises their mobility in terms of clinical functionality, comfort, posture, and skin integrity,” Babacan added.

Tom Hetzel, CEO and Co-Founder of Ride Designs, said: “We’re thrilled to become part of the Sunrise Medical group. Ride Designs has always been dedicated to helping wheelchair riders achieve the best possible fit to enhance their quality of life. This aligns seamlessly with Sunrise Medical’s mission of improving people’s lives. Ride Designs and the Aspen Seating Clinic have long been pioneers in specialised seating development. We’re especially proud of our latest 3D printing technology manufacturing capabilities.”

He added: “We’re very passionate to bring our advanced, clinically differentiated solutions to as many riders as possible. The strengths of the two companies complement each other very well. Sunrise Medical’s existing comprehensive mobility offering, global sales networks, business resources, and infrastructure will significantly accelerate Ride’s global outreach and expansion. We’re committed to providing uncompromising solutions to address skin and postural challenges, and we believe that Sunrise Medical is our strongest partner in achieving our mission.”

Ride Designs adds to Sunrise Medical’s strong track record in M&A which is a key pillar in its business strategy. Recent successful strategic acquisitions in 2022 include The Helping Hand Company, a UK-based company specializing in pressure management and pediatric products, and Budapest-headquartered NOW Technologies, a technological research and development company focusing on digital and software innovations of wheelchair control systems.

In 2020, Sunrise Medical also acquired James Leckey Design, along with its subsidiaries Firefly Friends and Vida Global, a global leader in specialized pediatric therapeutic devices, as well as Oracing, a Spanish designer and manufacturer of innovative made-to-measure sports wheelchairs and power assist products. With the Ride Designs acquisition, Sunrise Medical and Ride Designs aim to revolutionise the world of custom seating and further empower wheelchair riders to live their lives to the fullest.

For more information, please contact:
Carol Liu
Senior VP Corporate Development & Strategic Marketing, Sunrise Medical
e-mail: carol.liu@sunmed.com

About Sunrise Medical
Committed to improving people’s lives, Sunrise Medical is a world leader in design, manufacturing and distribution of innovative, high-quality assistive mobility products and services. Distributed in 130+ countries under its own 17 proprietary brands, the key products include manual and power wheelchairs, power assist products, motorised scooters, seating & positioning systems, and daily living aids. Operating in 23 countries, Sunrise Medical is headquartered in Malsch, Germany, and employs 2,600+ associates worldwide. To find out more, please visit www.sunrisemedical.com

About Ride Designs
Sharing in that commitment to improving people’s lives, Ride is committed to creating wheelchair seating systems that help protect skin, enhance mobility, improve function, and optimize posture. Ride Designs hosts the Aspen Seating Clinic at our Denver, Colorado headquarters where world class athletes and Paralympians, as well as the most discerning of wheelchair riders, come for seating solutions. With its beginnings in 1998, Ride Designs has expanded its presence across North America and beyond.

In a landmark move set to transform the orthopedic industry, Intech, a global leader in Medical Device manufacturing, is thrilled to announce that is has acquired Lenkbar LLC, Florida-based innovative Cutting Tool expert.

This strategic partnership establishes a worldwide entity that combines broad capabilities in precision machining with unmatched expertise in grinding of cutting tools, setting new standards in quality, innovation, and customer service.

“I am very excited about this union of forces and the endless possibilities it holds for our customers. Together, we are poised to advance minimally invasive surgery, cutting tools, and sports medicine, as we continue to push boundaries and articulate the future of Healthcare.“ Laurent Pruvost, President & CEO, Intech.

As a leading Medical Device manufacturing powerhouse, Intech has grown globally to become one of the most recognised Contract Design and Manufacturing Organization (“CDMO”) in Orthopedics.

Offering a true one-stop-shop platform, the company has been instrumental in supporting its customers around the globe with custom design and manufacturing of instruments, implants, cases and trays, as well as 3D-printed solutions. Intech’s dedication to delivering top-notch quality devices has earned the Group, backed by Montagu, an esteemed reputation in the industry.

The addition of Lenkbar and its articulated FlexMetric® technology to the Intech family pushes the Group’s offering to new heights. With an additional 30,000 sq.ft. facility in Naples, FL., Lenkbar adds vertically integrated capabilities that span from gun-drilling to grinding, taking drills, taps and handheld devices all the way to cleaning, passivation, and sterile packaging.

Lenkbar’s state-of-the-art infrastructure and cutting-edge technology has earned them a stellar reputation within the Trauma, Extremities and Sports Medicine space.

“Lenkbar is delighted to join the Intech group. Working with Laurent and his team will not only bolster our footprint and portfolio of solutions, but will also rapidly enable us to replicate critical processes at sister facilities.“ Erik Papenfuss, President & CEO, Lenkbar.

The merger of Intech and Lenkbar signifies a new era of growth and innovation in Orthopedics and beyond.

By combining strengths and expertise, the new group will deliver an unparalleled suite of products and services that are redefining the standard of care for patients around the world, from design and manufacturing to cleaning, passivation & sterile packaging.

Intech and Lenkbar will be exhibiting jointly at EuroSpine & NASS next month. The team looks forward to revealing a shared vision for the future and exploring new opportunities for tomorrow.

EQT Private Equity, together with its co-shareholders, to sell LimaCorporate to NYSE-listed Enovis Corporation

Under EQT Private Equity’s ownership, LimaCorporate has grown to be one of the leading European orthopaedic companies. EQT and LimaCorporate worked together to further empower surgeons with innovative orthopaedic implants that improve patient outcomes

Today, LimaCorporate’s products are sold in 49 countries across the globe with more than 130,000 implants delivered every year, with a strong focus on product innovation helping surgeons restore the “eMotion of Motion” in patients

EQT is pleased to announce that the EQT VII fund (“EQT Private Equity” or “EQT”), together with its co-shareholders, have agreed to sell LimaCorporate (the “Company”) to Enovis Corporation. With this transaction, LimaCorporate becomes part of the NYSE-listed Enovis Corporation in a strategic combination that creates a global leader in the orthopaedic industry.

Founded in 1945 by the Lualdi family and headquartered in San Daniele del Friuli, Italy, LimaCorporate is a global orthopaedic implant manufacturer with a heritage of innovation, reflected in its industry leading know-how in additive manufacturing, such as its proprietary Trabecular Titanium (“TT”) technology. The Company focuses on shoulder, knee and hip prostheses with a portfolio that includes one of the first modular shoulder systems in the world, the SMR, the Delta hip cup family, and the Physica system knee.

EQT has supported LimaCorporate in the expansion of its product portfolio primarily through in-house innovation and the advancement of its 3D printing capabilities. It has invested to solidify its core offering and increase manufacturing capacity in the face of rapidly growing demand, while further developing talent to execute on the Company’s market expansion, with accelerated global growth. In 2022, the Company reached revenues of EUR 249 million and it will continue to bring critical innovation to surgeons and patients as part of Enovis Corporation.

Matteo Thun, Partner within EQT Private Equity’s Advisory Team, said, “LimaCorporate is a true example of sophisticated engineering and technology designed to empower surgeons and to improve patients’ life. EQT is proud to have been part of the Company’s journey and I want to thank the management team and all the employees of LimaCorporate, who work enthusiastically every day to bring life-changing products to patients around the world. It is exciting to see a global player like Enovis Corporation joining forces with LimaCorporate in such a strategic combination”.

Massimo Calafiore, CEO of LimaCorporate, said, “I am really proud of what the people of LimaCorporate have achieved over the years and I thank EQT for their partnership. The combination with Enovis Corporation is a key milestone in our journey and I am looking forward to seeing the combined Group continue to develop innovative products for surgeons and patients globally”.

The transaction is subject to customary conditions and approvals and is expected to close in early 2024.

EQT has been advised by Goldman Sachs as lead financial advisor, Morgan Stanley, Mediobanca, Latham & Watkins and PwC.

Contact
EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

About EQT
EQT is a purpose-driven global investment organization with EUR 224 billion in total assets under management (EUR 126 billion in fee-paying assets under management) within two business segments – Private Capital and Real Assets. EQT owns portfolio companies and assets in Europe, Asia-Pacific and the Americas and supports them in achieving sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com
Follow EQT on LinkedIn, Twitter, YouTube and Instagram

About LimaCorporate
LimaCorporate is a global orthopedic company, focused on digital innovation and patient-tailored hardware, which advances patient-centred care.  Its pioneering technological solutions are developed to empower surgeons, and to improve patient outcomes from joint replacement surgery.  Its primary focus is on providing reconstructive and custom-made orthopedic solutions to surgeons, enabling them to improve the quality of life of patients by restoring the joy of movement.

Headquartered in Italy, the company operates directly in over 20 countries around the world. LimaCorporate offers products ranging from large joint revision and primary implants, to complete extremities solutions, including fixation.

For additional information on the Company, please visit www.limacorporate.com

About Enovis Corporation
Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV.

For more information about Enovis, please visit www.enovis.com

KIWA, a leading European institute dedicated to certifying processes and organizations, rewarded Zorgwerk with certifications regarding recognition for both ISO 9001:2015 and ISO 27001:2022.

ISO 9001:2015 is the international standard for quality management, while ISO 27001:2022 is the latest version of the global standard that provides guidelines for information security management.

Danielle Van der Burg, CEO of Zorgwerk stressed, “Our organization and platform are built on a continuous focus on quality, confidentiality and integrity. This is essential to deliver on our promises to clients and professionals. This year, we made the decision to have our quality and information security management systems certified by KIWA. Through their skilled auditors, who have specific knowledge and experience in our industry, we were assured of a thorough and in-depth assessment. I am incredibly proud of my entire team. Thanks to the structured approach we have been following for years, we immediately complied with the standards and are now certified for both ISO 9001 and ISO 27001, ensuring that we continue to improve our organization.”